Arrhythmogenic Right Ventricular Dysplasia in Neuromuscular Disorders

Objectives Arrhythmogenic right ventricular dysplasia (ARVD) is a rare, genetic disorder predominantly affecting the right ventricle. There is increasing evidence that in some cases, ARVD is due to mutations in genes, which have also been implicated in primary myopathies. This review gives an overvi...

Full description

Bibliographic Details
Main Authors: Josef Finsterer, Claudia Stöllberger
Format: Article
Language:English
Published: SAGE Publishing 2016-01-01
Series:Clinical Medicine Insights: Cardiology
Online Access:https://doi.org/10.4137/CMC.S38446
id doaj-a2eee45730fd450db02d96515ae3ec5c
record_format Article
spelling doaj-a2eee45730fd450db02d96515ae3ec5c2020-11-25T03:15:03ZengSAGE PublishingClinical Medicine Insights: Cardiology1179-54682016-01-011010.4137/CMC.S38446Arrhythmogenic Right Ventricular Dysplasia in Neuromuscular DisordersJosef Finsterer0Claudia Stöllberger1Krankenanstalt Rudolfstiftung, Vienna, Austria.Krankenanstalt Rudolfstiftung, Vienna, Austria.Objectives Arrhythmogenic right ventricular dysplasia (ARVD) is a rare, genetic disorder predominantly affecting the right ventricle. There is increasing evidence that in some cases, ARVD is due to mutations in genes, which have also been implicated in primary myopathies. This review gives an overview about myopathy-associated ARVD and how these patients can be managed. Methods A literature review was done using appropriate search terms. Results The myopathy, which is most frequently associated with ARVD, is the myofibrillar myopathy due to desmin mutations. Only in a single patient, ARVD was described in myotonic dystrophy type 1. However, there are a number of genes causing either myopathy or ARVD. These genes include lamin A/C, ZASP/cypher, transmembrane protein-43, titin, and the ryanodine receptor-2 gene. Diagnosis and treatment are identical for myopathy-associated ARVD and nonmyopathy-associated ARVD. Conclusions Patients with primary myopathy due to mutations in the desmin, dystrophia myotonica protein kinase, lamin A/C, ZASP/cypher, transmembrane protein-43, titin, or the ryanodine receptor-2 gene should be screened for ARVD. Patients carrying a pathogenic variant in any of these genes should undergo annual cardiological investigations for cardiac function and arrhythmias.https://doi.org/10.4137/CMC.S38446
collection DOAJ
language English
format Article
sources DOAJ
author Josef Finsterer
Claudia Stöllberger
spellingShingle Josef Finsterer
Claudia Stöllberger
Arrhythmogenic Right Ventricular Dysplasia in Neuromuscular Disorders
Clinical Medicine Insights: Cardiology
author_facet Josef Finsterer
Claudia Stöllberger
author_sort Josef Finsterer
title Arrhythmogenic Right Ventricular Dysplasia in Neuromuscular Disorders
title_short Arrhythmogenic Right Ventricular Dysplasia in Neuromuscular Disorders
title_full Arrhythmogenic Right Ventricular Dysplasia in Neuromuscular Disorders
title_fullStr Arrhythmogenic Right Ventricular Dysplasia in Neuromuscular Disorders
title_full_unstemmed Arrhythmogenic Right Ventricular Dysplasia in Neuromuscular Disorders
title_sort arrhythmogenic right ventricular dysplasia in neuromuscular disorders
publisher SAGE Publishing
series Clinical Medicine Insights: Cardiology
issn 1179-5468
publishDate 2016-01-01
description Objectives Arrhythmogenic right ventricular dysplasia (ARVD) is a rare, genetic disorder predominantly affecting the right ventricle. There is increasing evidence that in some cases, ARVD is due to mutations in genes, which have also been implicated in primary myopathies. This review gives an overview about myopathy-associated ARVD and how these patients can be managed. Methods A literature review was done using appropriate search terms. Results The myopathy, which is most frequently associated with ARVD, is the myofibrillar myopathy due to desmin mutations. Only in a single patient, ARVD was described in myotonic dystrophy type 1. However, there are a number of genes causing either myopathy or ARVD. These genes include lamin A/C, ZASP/cypher, transmembrane protein-43, titin, and the ryanodine receptor-2 gene. Diagnosis and treatment are identical for myopathy-associated ARVD and nonmyopathy-associated ARVD. Conclusions Patients with primary myopathy due to mutations in the desmin, dystrophia myotonica protein kinase, lamin A/C, ZASP/cypher, transmembrane protein-43, titin, or the ryanodine receptor-2 gene should be screened for ARVD. Patients carrying a pathogenic variant in any of these genes should undergo annual cardiological investigations for cardiac function and arrhythmias.
url https://doi.org/10.4137/CMC.S38446
work_keys_str_mv AT joseffinsterer arrhythmogenicrightventriculardysplasiainneuromusculardisorders
AT claudiastollberger arrhythmogenicrightventriculardysplasiainneuromusculardisorders
_version_ 1724640757724217344